Acucela Email Format
Biotechnology ResearchWashington, United States11-50 Employees
Acucela Inc. is a Seattle-based biotechnology firm focused on ophthalmology and is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. The organization advances a pipeline of drugs and devices intended to preserve or restore vision for people worldwide. Its drug development targets retinal conditions such as retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, age-related macular degeneration, Stargardt disease, cataract, and presbyopia, alongside a patient-facing monitoring device for neovascular retinal diseases. Based in Seattle, it operates as a small biotechnology company within a larger corporate group. In May 2019, Acucela appointed Robert J. Stevens to its Board of Directors, marking a governance development.